Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACBFF Aurora Cannabis	$5.23 +4.8%	$4.63	$2.20 ▼ $12.53	$5.03B	N/A	4.22 million shs	2.53 million shs
CRSP CRISPR Therapeutics	$54.88 +1.4%	$55.00	$30.04 ▼ $71.13	$4.99B	1.8	2.59 million shs	1.27 million shs
EVTCY Evotec	$3.57 -1.9%	$4.00	$14.22 ▼ $26.57	$1.18B	0.98	2,407 shs	33,224 shs
TGTX TG Therapeutics	$28.28 -0.9%	$33.95	$21.11 ▼ $46.48	$4.49B	1.95	2.48 million shs	1.53 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACBFF Aurora Cannabis	0.00%	-1.77%	+3.10%	-9.27%	-23.35%
CRSP CRISPR Therapeutics	-0.35%	-6.01%	-16.41%	+44.08%	+11.17%
EVTCY Evotec	0.00%	-3.19%	-14.55%	-23.04%	+8.66%
TGTX TG Therapeutics	-3.09%	+2.88%	-22.68%	-19.04%	+16.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	3.6343 of 5 stars	4.3	3.0	0.0	0.0	2.2	3.3	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	4.4045 of 5 stars	3.4	1.0	0.0	3.5	3.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACBFF Aurora Cannabis	0.00	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	30.47% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	63.54% Upside

Current Analyst Ratings Breakdown

Latest EVTCY, CRSP, ACBFF, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	$37.31M	133.78	N/A	N/A	$22.64 per share	2.42
EVTCY Evotec	$572.16M	2.06	$0.03 per share	105.53	$2.52 per share	1.42
TGTX TG Therapeutics	$329M	13.64	$0.12 per share	245.45	$1.43 per share	19.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACBFF Aurora Cannabis	N/A	$0.12	43.58	∞	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	8.71	∞	N/A	20.85%	16.02%	7.81%	N/A
TGTX TG Therapeutics	$23.38M	$0.37	76.43	28.28	N/A	13.31%	26.05%	9.58%	11/3/2025 (Estimated)

Latest EVTCY, CRSP, ACBFF, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACBFF Aurora Cannabis	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	16.61	16.61
EVTCY Evotec	0.53	2.57	2.50
TGTX TG Therapeutics	0.89	3.86	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACBFF Aurora Cannabis	N/A
CRSP CRISPR Therapeutics	69.20%
EVTCY Evotec	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ACBFF Aurora Cannabis	N/A
CRSP CRISPR Therapeutics	4.10%
EVTCY Evotec	N/A
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACBFF Aurora Cannabis	1,340	960.96 million	N/A	Not Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable

EVTCY, CRSP, ACBFF, and TGTX Headlines

Recent News About These Companies

Wellington Management Group LLP Boosts Position in TG Therapeutics, Inc. $TGTX

August 26 at 4:15 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Position Decreased by 1832 Asset Management L.P.

August 25 at 6:17 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLC

August 23 at 5:04 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd.

August 23 at 4:26 AM | marketbeat.com

TG Therapeutics: Looking For The Stimulus For A Turnaround

August 20, 2025 | seekingalpha.com

Fox Run Management L.L.C. Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 19, 2025 | marketbeat.com

746,696 Shares in TG Therapeutics, Inc. $TGTX Bought by Nuveen LLC

August 19, 2025 | marketbeat.com

Invesco Ltd. Raises Position in TG Therapeutics, Inc. $TGTX

August 19, 2025 | marketbeat.com

Wealthedge Investment Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

Sector Gamma AS Acquires Shares of 55,000 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

TG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You Think

August 16, 2025 | finance.yahoo.com

Aigen Investment Management LP Purchases Shares of 9,522 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 14, 2025 | marketbeat.com

Persistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment Board

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LP

August 13, 2025 | marketbeat.com

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10, 2025 | marketbeat.com

TG Therapeutics files automatic mixed securities shelf

August 9, 2025 | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8, 2025 | gurufocus.com

What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

August 8, 2025 | marketbeat.com

B. Riley Has Bullish Outlook for TG Therapeutics Q4 Earnings

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVTCY, CRSP, ACBFF, and TGTX Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

$5.23 +0.24 (+4.81%)

As of 08/25/2025

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.

CRISPR Therapeutics NASDAQ:CRSP

$54.88 +0.75 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$54.75 -0.13 (-0.24%)

As of 05:05 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Evotec OTCMKTS:EVTCY

$3.57 -0.07 (-1.92%)

As of 08/25/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

TG Therapeutics NASDAQ:TGTX

$28.28 -0.25 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$28.28 0.00 (0.00%)

As of 04:39 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time